VE 416
Alternative Names: VE-416Latest Information Update: 30 Nov 2023
At a glance
- Originator Vedanta Biosciences
- Class Antiallergics; Bacteria; Food allergy immunotherapies
- Mechanism of Action Immunomodulators; Microbiome modulators; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Peanut hypersensitivity
Most Recent Events
- 28 Nov 2023 Vedanta Biosciences has patent protection for cover compositions of clostridia bacterial species in European Union
- 01 Jul 2019 Phase-I/II clinical trials in Peanut hypersensitivity (In adolescents, In adults, Combination therapy) in USA (PO, Capsule) (NCT03936998)
- 01 Jul 2019 Phase-I/II clinical trials in Peanut hypersensitivity (In adolescents, In adults, Monotherapy) in USA (PO, Capsule) (NCT03936998)